Rare Disease Treatment Unexpectedly Rejected by the FDA

September 4, 2019

Rare Disease Treatment Unexpectedly Rejected by the FDA

In a surprise decision, the U.S. Food and Drug Administration has rejected Sarepta’s experimental exon-skipping drug Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy, citing risks of both infection and kidney toxicity. Yourway is dedicated to supporting clinical trials for advanced therapies for orphan diseases.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Schedule a Meeting

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Schedule a Meeting

Media

Articles

Global Reach in Clinical Trials: Beyond Presence to True Execution

Open chat

Hello! How can I help you?